Overview
AbolerIS Pharma, announced on November 4, the successful completion of a €2.5 million ($2.9M) seed financing round with an investment consortium comprised of Newton Biocapital and Turenne Santé / Sham Innovation Santé. This funding will allow AbolerIS Pharma to develop technologies that preserve and stimulate regulatory T cells and control/eliminate the effector T cells responsible for immune system diseases.
Aboleris Pharma is a pre-clinical stage biotechnology company specializing in the development of innovative immuno-modulators for the treatment of transplant rejection, graft-versus-host disease and autoimmune diseases.
McDermott Will & Emery acted as corporate counsel along with AbolerIS Pharma with Anthony Paronneau, partner, Mathilde Peschard and Pascaline Sagot, associates.
Turenne Santé/Sham and Newton Biocapital were advised by Chammas & Marcheteau.
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. With 21 locations on three continents, our team works seamlessly across practices, industries and geographies to deliver highly effective – and often unexpected – solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
